Clinical Trials Logo

Parkinson Disease clinical trials

View clinical trials related to Parkinson Disease.

Filter by:

NCT ID: NCT04114994 Recruiting - Multiple Sclerosis Clinical Trials

Longitudinal Cognitive Assessment by BoCA

BoCA
Start date: October 1, 2019
Phase:
Study type: Observational

The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals.

NCT ID: NCT04108741 Recruiting - Parkinson Disease Clinical Trials

Augmented Reality Treadmill Training in Patients With Parkinson's Disease

Falls_in_PD
Start date: September 15, 2020
Phase: N/A
Study type: Interventional

Gait disorder is a disabling symptom in Parkinson's disease (PD) affecting all patients during the course. Three methods of treadmill training (TT) will be compared to assess additional augmented reality (AR), or additional dual task (DT). AR TT, DT TT, and TT alone applied over 3 weeks at each day will be compared for their impact on falls, walking, freezing and attention for 3 months in a double blinded randomized controlled trial during regular neurorehabilitation.

NCT ID: NCT04101968 Recruiting - Parkinson Disease Clinical Trials

The GBA Multimodal Study in Parkinson's Disease

Start date: May 1, 2019
Phase:
Study type: Observational

This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will also use a technology-based assessment to study the typing patterns as possible biomarkers of early motor dysfunctions.

NCT ID: NCT04097080 Recruiting - Parkinson Disease Clinical Trials

Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease

Start date: December 15, 2019
Phase: Phase 1
Study type: Interventional

This study evaluates the hypothesis that the gas mixture with xenon will have a positive effect on the symptoms in patients with Parkinson's Disease. The study will test the hypothesis that the gas mixture with xenon has a symptomatic treatment potential for patients with Parkinson's Disease, as measured by change from baseline in the Unified Parkinson Disease Rating Scale (UPDRS).

NCT ID: NCT04093544 Recruiting - Parkinson Disease Clinical Trials

Expanding the Therapeutic Window of Deep Brain Stimulation in Parkinson's Disease by Means of Directional Leads

Start date: May 15, 2018
Phase: N/A
Study type: Interventional

Exploring directional lead

NCT ID: NCT04090385 Recruiting - Parkinson Disease Clinical Trials

Multifocal Neuromodulation in Motor and Cognitive Function of People With Parkinson's Disease

Start date: January 30, 2020
Phase: N/A
Study type: Interventional

People with Parkinson's disease (PD) experience various motor and nonmotor symptoms throughout its evolution. It is characterized mainly by the presence of tremor, stiffness, bradykinesia and postural instability, leading to progressive functional limitation and impairment in the performance of usual activities of daily living. In addition, patients may have cognitive disorders, memory deficits, problems related to visuospatial dysfunction, difficulties in performing sequential or repetitive movements, freezing, and slow psychological responses. Previous studies analyzed by systematic reviews suggest the efficacy of Transcranial Direct Current Stimulation (tDCS) to improve the motor and non-motor symptoms of PD, depending on the area of stimulation. However, most of these focus only on one specific area. Therefore, the overall objective of this study is to investigate the effects of multifocal neuromodulation on the motor and cognitive function of people with Parkinson's disease.

NCT ID: NCT04087031 Recruiting - Parkinson Disease Clinical Trials

Innovative Models in the Rehabilitation of the Elderly With Parkinson's Disease Through Technological Innovation

Start date: December 3, 2019
Phase: N/A
Study type: Interventional

The final goal of the present study is to propose a new approach in the Parkinson's Disease rehabilitation, focused on the use of robotic devices and to check the results not only at the end of the treatment but also in the long term, foreseeing 3 follow-up.

NCT ID: NCT04071847 Recruiting - Parkinson Disease Clinical Trials

Abbott DBS Post-Market Study of Outcomes for Indications Over Time

ADROIT
Start date: November 26, 2019
Phase:
Study type: Observational

The purpose of this international study is to evaluate long-term safety and effectiveness of Abbott deep brain stimulation (DBS) systems for all indications, including Parkinson's disease, essential tremor or other disabling tremor and dystonia.

NCT ID: NCT04064294 Recruiting - Parkinson Disease Clinical Trials

Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors

STAT-PD
Start date: June 1, 2019
Phase:
Study type: Observational

In this study, the investigators will examine the association of statin use and dyskinesia in a convenience sample Parkinson's disease patients in the Veterans Administration Health Care System.

NCT ID: NCT04062279 Recruiting - Parkinson Disease Clinical Trials

Predictors of Parkinson's Disease Progression

PDPROG-EGY
Start date: November 15, 2019
Phase:
Study type: Observational [Patient Registry]

it is a prospective longitudinal observational study, aiming to to identify clinical, and biochemical baseline predictors of motor and non-motor PD progression in sample of Egyptian patients. it measures the baseline motor, non-motor, biochemical and imaging characteristics at enrollment and its relation to PD progression over 3 years